fotemustine has been researched along with imiquimod in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bonnard, V; Bonnet, PA; Bressolle, F; Deleuze-Masquefa, C; Gayraud-Paniagua, S; Moarbess, G; Pinguet, F; Vidal, JR | 1 |
| Bonnet, PA; Bressolle, F; David, N; Deleuze-Masquefa, C; Gayraud-Paniagua, S; Khier, S; Moarbess, G; Pinguet, F | 1 |
| Binder, B; Cerroni, L; Kerl, H; Richtig, E; Smolle, J; Wolf, IH | 1 |
| Bonnet, PA; Bressolle, FM; Cooper, JF; Deleuze-Masquéfa, C; Gattacceca, F; Khier, S; Margout, D; Moarbess, G; Pinguet, F; Solassol, I | 1 |
4 other study(ies) available for fotemustine and imiquimod
| Article | Year |
|---|---|
In vitro and in vivo anti-tumoral activities of imidazo[1,2-a]quinoxaline, imidazo[1,5-a]quinoxaline, and pyrazolo[1,5-a]quinoxaline derivatives.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Databases, Factual; Female; Humans; Imidazoles; Mice; Mice, Nude; Molecular Structure; Pyrazoles; Quinoxalines; Xenograft Model Antitumor Assays | 2008 |
New imidazo[1,2-a]quinoxaline derivatives: synthesis and in vitro activity against human melanoma.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Imidazoles; Melanoma; Quinoxalines; Structure-Activity Relationship | 2009 |
Topical imiquimod in the treatment of metastatic melanoma to skin.
Topics: Adjuvants, Immunologic; Administration, Cutaneous; Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Dacarbazine; Female; Humans; Imiquimod; Interferon alpha-2; Interferon-alpha; Knee; Leg; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Nitrosourea Compounds; Organophosphorus Compounds; Recombinant Proteins; Scalp; Skin Neoplasms; Treatment Outcome | 2003 |
Pharmacology of EAPB0203, a novel imidazo[1,2-a]quinoxaline derivative with anti-tumoral activity on melanoma.
Topics: Aminoquinolines; Animals; Antineoplastic Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; Humans; Imidazoles; Imiquimod; Injections, Intraperitoneal; Injections, Intravenous; Male; Melanoma; Mice; Mice, Nude; Nitrosourea Compounds; Organophosphorus Compounds; Quinoxalines; Rats; Skin Neoplasms; Xenograft Model Antitumor Assays | 2010 |